# Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

> **NCT01785849** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 508 (actual)

## Conditions studied

- Hyperparathyroidism, Secondary

## Interventions

- **DRUG:** Etelcalcetide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01785849
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-12
- **Primary completion:** 2014-05-22
- **Final completion:** 2014-06-12
- **Target enrollment:** 508 (ACTUAL)
- **Last updated:** 2019-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01785849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01785849, "Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01785849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*